BCL2 and colorectal carcinoma: One of the hypothesis explaining resistance to oxaliplatin, 5-FU and tyrosine-kinase inhibitors (TKIs) in CRC and other tumors, involves the failure of Mcl1 degradation, the anti-apoptotic protein belonging to the BCL2 family, that is another well-known substrate of FBXW7 [16,21].